Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gliomas and if adjuvant therapy with the chemotherapeutic agent temozolomide would enhance the cytotoxic properties of TRAIL in glioma lines resistant to TRAIL monotherapy. We have engineered adeno-associated virus (AAV) vectors encoding recombinant secreted TRAIL (S-TRAIL) and bioluminescentfluorescent marker fusion proteins and show that AAVdelivered S-TRAIL leads to varying degrees of killing in multiple glioma lines, which correspond with caspase-3/7 activation. In vivo, dual bioluminescent imaging revealed efficient delivery of therapeutic AAV vectors directly into the tumor mass, which induced marked attenuation of tumor progression. Treatment of glioma cells with the chemotherapeutic agent temozolomide alone lead to a significant accumulation of cells in G 2 -M phase, activated the cell cycle checkpoint protein Chk1, and increased death receptor expression in a time-dependent manner. Furthermore, combined treatment with AAV-S-TRAIL or neural stem cell-S-TRAIL and temozolomide induced cell killing and markedly up-regulated proapoptotic proteins in glioma cells least sensitive to TRAIL. This study elucidates novel means of delivering S-TRAIL to gliomas and suggests combination of clinically relevant temozolomide and S-TRAIL may represent a new therapeutic option with increased potency for glioblastoma patients. [Mol Cancer Ther 2008;7(11):3575 -85] 
Introduction
Glioblastoma multiforme is the most common brain tumor comprising 23% of all primary adult brain tumors and is the most deadly with a life expectancy of 9 to 12 months (1). Despite extensive investigation, glioblastoma multiforme remains resistant to all current therapies, with resection, radiotherapy, and chemotherapy minimally prolonging survival and ultimate redevelopment of tumors leading to patient mortality (2) . Recently, tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) has arisen as a promising new antiglioma therapy due to its ability to induce apoptosis in a wide variety of malignant cells with high tolerance and minimal toxicity to normal tissue (3 -7) . Purified TRAIL protein has been shown to induce apoptosis in several different glioma lines in vitro (8 -10), whereas both local and systemic injection of TRAIL protein exerts antitumor effects on intracranial human malignant glioma xenografts in mice (11) . Despite initial clinical excitement, the rapid clearance of soluble TRAIL following systemic administration and large dose required to achieve glioma regression have limited the effectiveness of TRAIL in patients (12 -14) . Additionally, numerous studies have shown that a large percentage of primary glioma lines are resistant to TRAIL-induced apoptosis (15, 16) . Therefore, methods to improve both efficiency of delivery and tumoricidal activity of TRAIL are required.
Two major strategies that have been used to overcome the problems of delivery encountered with recombinant proteins are viral gene therapy and cell-based therapy. Viral vectors are advantageous in that viral gene therapy can deliver robust and long-term expression of therapeutic proteins with high specificity in local tissue, reducing the systemic dose and nonspecific toxicity (17) . In particular, adeno-associated virus (AAV) has received much attention in both clinical and nonclinical research due to the ability of AAV to induce high levels of transgene expression in glioma cells with minimal associated toxicity or host immune response (18 -21) . Alternatively, neural stem cells (NSC) have arisen as new therapeutic agents for the treatment of diseases of the central nervous system due to their unique tumor-specific homing properties, potential to differentiate into different neural cell types, and incorporate into the cytoarchitecture of the brain following transplantation (3, 22 -24) . Capitalizing on these properties, we and others have shown the feasibility of engineering therapeutic NSC that can efficiently delivery antitumor proteins and result in tumor regression (3, 25 -27) . To improve the efficacy of TRAIL, we also created a novel form of TRAIL consisting of the extracellular domain of Flt3 ligand fused to the NH 2 terminus of the extracellular domain of secreted TRAIL (S-TRAIL; ref. 28 ) and showed that S-TRAIL had potent bystander effects on neighboring glioma cells as well as increased cell-killing effects (4, 28) . Engineering NSC with S-TRAIL (NSC-S-TRAIL), we further showed that NSC selectively migrate to established gliomas where delivery of S-TRAIL by NSC inhibited progression of human glioma xenografts assessed by serial dual bioluminescent imaging (3, 23, 27) .
In an effort to improve the efficacy of TRAIL therapy and overcome TRAIL resistance, TRAIL-based combination therapies have also been investigated (7, 29, 30) . Temozolomide is an oral alkylating agent used extensively in clinics as part of the chemotherapeutic regimen for treatment of high-grade glioma (31, 32). Temozolomide is a small molecule that effectively traverses the blood-brain barrier where it induces glioma cell death by causing accumulations of DNA mismatch, subsequent growth arrest, and eventually apoptosis (32, 33) . Recently, studies using bacterially expressed TRAIL have highlighted a potential synergy between temozolomide and TRAIL, showing combined bacterially expressed TRAIL and temozolomide treatment had improved antitumor effects on cultured glioma cells (34) . Further, convection-enhanced delivery of TRAIL protein combined with systemic administration of temozolomide proved more effective than either therapy alone in mouse models (35) . These studies suggest temozolomide may sensitize cells to TRAIL-induced apoptosis; however, the underlying signaling mechanisms remain poorly understood and it is unclear whether temozolomide can enhance the killing effects of recombinant S-TRAIL delivered by novel and highly efficient AAV or NSC in glioma lines that are resistant to S-TRAIL monotherapy.
In this study, we (a) developed novel AAV encoding S-TRAIL and fusions between fluorescent and bioluminescent marker genes and investigated the antiglioma properties of AAV-S-TRAIL in vitro using different human glioma lines and in vivo in human glioma xenograft models, (b) evaluated the effects of temozolomide on glioma cells with varying resistance to TRAIL, and (c) evaluated the synergistic effect of therapeutic AAV-S-TRAIL and the previously developed NSC-S-TRAIL and temozolomide in human glioma cell lines with varying degrees of TRAIL resistance.
Materials and Methods

Viral Vector Generation
The recombinant Gaussia luciferase (Gluc)-DsRed2 and S-TRAIL were constructed in the AAV-MCS6 plasmid that was kindly provided by the Harvard Gene Therapy Initiative (Harvard Institute of Medicine). To first generate the Gluc and DsRed2 fusion, a 569-bp Gluc fragment was obtained from pGluc-Basic Vector (New England Biolabs) by PCR using the forward primer 5 ¶-CTAGCTAGCGTC-GACATGGGAGTCAAAGTTCTGTTTGCC-3 ¶ bearing NheI and Sal I restriction sites and the reverse primer 5 ¶-CCGCTCGAGGATATCGTCACCACCGGCCCCCTT-GAT-3 ¶ bearing EcoRV and XhoI restriction sites. The 684-bp DsRed2 fragment was similarly generated by PCR from the vector LV-firefly luciferase (Fluc)-DsRed2 (36) using the forward primer 5 ¶-CCGATATCATGGCCTC-CTCCGAGAACGTC-3 ¶ bearing an EcoRV restriction site and the reverse primer 5 ¶-CCGCTCGAGGCGGCCGCCTA-CAGGAACAGGTGGTGGCG-3 ¶ bearing NotI and XhoI restriction sites. The two fragments were ligated into SalI/NotI digested pIRES vector (Clontech Laboratories). To generate Gluc-DsRed2, a 1,898-bp fragment containing the IRES element and Gluc-DsRed2 was excised from the pIRES vector by digestion with EcoRI/NotI and ligated into EcoRI/NotI digested AAV-MCS6 vector. To generate AAV-S-TRAIL, the 1,200-bp fragment encoding S-TRAIL was obtained from LV-S-TRAIL (23) by PCR using a forward primer 5 ¶-CGGAATTCATGACAGTGCTGGCGC-CAGCC-3 ¶ containing an EcoRI restriction site and a reverse primer 5 ¶-CGACGCGTTTAGCCAACTAAAAAGGCCCC-GAA-3 ¶ containing a MluI restriction site. This fragment was ligated into EcoRI/MluI digested Gluc-DsRed2 vector to obtain AAV-S-TRAIL. Packaging and purification of recombinant AAV were done as described previously (37) , and typical titers were 1 Â 10 11 particles/mL. The generation and packaging of LV-green fluorescent protein (GFP)-Fluc has been described previously (36) .
Cell Lines Human glioma cell lines Gli36 expressing a constitutively active mutant epidermal growth factor receptor (EGFR; Gli36-EGFRvIII), U251, U87, and 293T cells were cultured in DMEM (Invitrogen) supplemented with 10% heatincubated fetal bovine serum, 100 Ag/mL penicillin, and 100 Ag/mL streptomycin. Previous results confirmed expression of the mutant EGFR receptor in Gli36-EGFRvIII cells was shown to have no influence on TRAIL sensitivity (8) . The neural progenitor cell line C17.2 has been described previously (23) . Creation and characterization of the cell line Gli36-EGFRvIII-GFP-Fluc has been described previously (36) . All cells were incubated at 37jC in a humidified 5% CO 2 incubator.
In vitro Fluorescence Microscopy, Bioluminescent Imaging, and Flow Cytometry
For visualization of DsRed2, 1 Â 10 5 293T cells were plated in 24-well plates. Twenty-hour hours later, cells were transduced with 1,000 multiplicities of infection (MOI) of either Gluc-DsRed2 or S-TRAIL, and 48 h posttransduction, DsRed2 fluorescence was visualized. To confirm a linear correlation between viral transduction and Gluc photon emission, 1 Â 10 4 293T cells were seated for 24 h in 96-well plates. Cells were then transduced with increasing MOI of either Gluc-DsRed2 or S-TRAIL for 24 h, at which time cells were incubated with 15 Ag coelenterazine for 10 min, and photon emission was measured using a cryogenically cooled high-efficiency CCD camera system (Roper Scientific). For flow cytometry, Gli36-EGFRvIII glioma cells were transduced with LV-GFP-Fluc using a MOI of 1. Following expansion in culture, the cells were analyzed by flow cytometry (FACSCalibur, BD Biosciences) to confirm GFP-positive cells.
S-TRAIL ELISA To determine the concentration of S-TRAIL released by AAV-S-TRAIL transduced cells, 0.4 Â 10 6 TRAIL-resistant 293T cells were transduced with increasing MOI of control virus (Gluc-DsRed2) or S-TRAIL. Twenty-four hours later, medium was collected and TRAIL protein concentration in the medium of transduced cells was measured using the TRAIL Immunoassay Kit (Biosource International) according to the manufacturer's protocol with wells coated with human TRAIL monoclonal antibody and soluble biotinylated TRAIL polyclonal antibody. Plates were read at 450 nm using an absorbance plate reader (Molecular Devices), and the data were analyzed by SOFTMAX.
Caspase and Viability Assays To determine the effect of S-TRAIL on cell viability and caspase activation, Gli36-EGFRvIII, U87, or U251 glioma cells were seeded in 96-well plates (1 Â 10 4 per well). Twenty-four hours after plating, the cells were transduced with AAV-Gluc-DsRed2 or AAV-S-TRAIL at increasing MOI (0-10,000). For viability, aggregate metabolic activity was measured using an ATP-dependent luminescent reagent (CellTiter-Glo; Promega). Caspase activity was determined with a caged, caspase-3/7-activatable DEVDaminoluciferin (Caspase-Glo-3/7; Promega). Assays were done according to the manufacturer's instructions and plates were read in a luminometer at 5 s/well. To investigate the synergistic effects of temozolomide and S-TRAIL, Gli36-EGFRvIII or U251 cells were plated as described above. Cells were treated with medium containing increasing concentrations of temozolomide (0-1,000 Amol/L) alone or in combination with the viral vectors S-TRAIL (0-4,000 MOI) or Gluc-DsRed2 (4,000 MOI) or S-TRAIL-containing medium from NSC (0-600 ng/mL) for 18 h and cell viability was determined as described above. To measure the effects of temozolomide pretreatment on S-TRAIL/temozolomide, U251 glioma cells were plated in 96-well plates and left untreated or incubated with temozolomide (100 and 500 Amol/L) for 24 h. New medium containing fresh temozolomide and control virus AAV-GlucDsRed2 (4,000 MOI), AAV-S-TRAIL (1,000 and 4,000 MOI), or NSC-S-TRAIL (200 and 600 ng/mL) was then added to both pretreated and nontreated cells, and viability or caspase activation was determined 18 h later.
Cell Cycle Analysis Following treatment with temozolomide (100 Amol/L; 24 and 72 h), untreated and temozolomide-treated cells (Gli36-EGFRvIII and U251) were pulsed for 1 h with bromodeoxyuridine (Amersham). The cells were trypsinized and fixed in cold ethanol and denatured in 2 mol/L HCl, 0.5% Triton X-100, which was neutralized in 0.1 mol/L borate (pH 8.5). Bromodeoxyuridine incorporation was detected by incubating cells with anti-bromodeoxyuridine antibody (Becton Dickinson) for 30 min at room temperature. The cells were washed and incubated with FITC-conjugated anti-mouse antibody (Vector Labs) for 30 min. Following a second wash, the cells were incubated with propidium iodide (10 Ag/mL propidium iodide; Sigma) and RNase A (250 Ag/mL; Sigma) at 4jC overnight and analyzed using a Becton Dickinson FACSort flow cytometer and CellQuest software.
Cell Implantation and In vivo Bioluminescent Imaging Gli36-EGFRvIII glioma cells transduced with LV-GFPFluc (Gli36-EGFRvIII-GFP-Fluc) has been described previously (36) . Briefly, cells were transduced with LV-GFP-Fluc in growth medium containing 12 Ag/mL polybrene (Fisher Scientific), visualized for GFP to confirm transduction, and expanded. Under inhaled anesthesia (1-2% isoflurane + 2 L O 2 ), 6 Â 10 6 Gli36-EGFRvIII-GFP-Fluc cells in 50 AL saline were implanted s.c. into athymic nude mice (nu/nu; ages 6-7 weeks; Charles River Laboratories) using a 28 gauge syringe. Two days post-implantation, 1 Â 10 9 particles of either AAV-Gluc-DsRed2 or AAV-S-TRAIL were directly injected into the tumor using a glass Hamilton syringe. A second injection of virus was administered 2 days after the initial injection. To serially monitor changes in glioma volume, mice were imaged for Fluc activity 1, 4, 7, and 12 days after the first injection of virus. D-Luciferin (4.5 mg/animal in 150 AL saline) was administered to each mouse by i.p. injection, and photon counts were recorded 5 min after D-luciferin administration with a 5 min acquisition time. Gluc imaging to visualize viral transgene expression within the tumor mass was done on mice 10 and 12 days after injection of Gluc-DsRed2. To visualize Gluc expression, mice received i.v. injection of coelenterazine (3.3 Ag/g body weight) and were imaged for Gluc activity using a 5 min acquisition time 10 days post-injection of AAV. Fluc imaging to visualize tumor volume was done as described above on day 12. Postprocessing and visualization of all images was done as described previously (23, 38) .
Immunohistochemistry Seven days post-transduction by AAV, tumors were removed, placed in 10% formalin, and embedded in paraffin. Sections (10 Am) were generated and subjected to an antigen retrieval process using a sodium citrate. Sections were stained for active caspase-3/7 staining (1:50; Calbiochem) according to standard protocols followed by processing for H&E by standard techniques.
Western Blot Analysis and Immunocytochemistry To investigate the effects of temozolomide alone, U251 cells were treated with temozolomide (100 Amol/L) for 24 or 72 h or left untreated. To determine the effects of combined temozolomide and S-TRAIL treatment on cells, U251 cells were treated for 24 h with temozolomide (500 Amol/L), NSC-S-TRAIL (600 ng/mL), a combination of temozolomide and S-TRAIL, or temozolomide and S-TRAIL following 24 h of sensitization by temozolomide alone. For all treatment groups, proteins were isolated from harvested cells, resolved by SDS-PAGE, and immunoblotted with antibodies against cleaved poly(ADP-ribose) polymerase (Cell Signaling), DR4 (Sigma-Aldrich), Chk1 (Santa Cruz Biotechnology), phosphorylated Chk1 (Cell Signaling), or a-tubulin (Sigma-Aldrich) antibodies and detected by chemiluminescence following incubation with horseradish peroxidase-conjugated secondary antibodies. An additional group of cells plated on coverslips was similarly treated with temozolomide or S-TRAIL, fixed, permeabilized, and incubated with a cleaved caspase-3 antibody (1:200; Cell Signaling) for 1 h at 37jC. Cells were then washed and incubated with goat anti-rabbit Alexa dye (540 nm)-conjugated secondary antibody (Molecular Probes) for 1 h, washed again, mounted, and examined by fluorescence microscopy.
Statistical Analysis Data are expressed as mean F SD and analyzed by either Student's t test or ANOVA (after Bartlett's test of homogeneity of variance) followed by the Newman-Keuls' correction for multiple comparisons. Differences were considered significant at P < 0.05. Synergy between S-TRAIL and temozolomide was determined by the isobologram method (39) . Gli36-EGFRvIII and U251 cells were treated with temozolomide at increasing concentrations alone or in combination with NSC-S-TRAIL or AAV-S-TRAIL for 18 h, at which time cell viability was determined and EC 50 values were calculated for each drug alone or in combination with a fixed ratio of the second drug. The calculated EC 50 values of each drug in combination were divided by the EC 50 of each drug alone. An isobologram was generated where the dotted line connecting the EC 50 of each drug alone represents the predicted additive value, values below the line indicate synergy and values above the line indicate antagonistic effects.
Results
To investigate the antiglioma potential of S-TRAIL delivered by AAV and simultaneously monitor transgene expression, we developed novel bimodal recombinant AAV vectors expressing a fusion of bioluminescent protein Gluc and DsRed2 (Fig. 1A) . Fluorescence microscopy of TRAIL-resistant 293T cells transduced with AAVGluc-DsRed2 or AAV-S-TRAIL revealed robust DsRed2 expression (Fig. 1B) , whereas bioluminescent imaging of AAV-Gluc-DsRed2 or AAV-S-TRAIL revealed strong Gluc signal that correlated linearly with viral concentration (Fig. 1C) . ELISA on culture medium of the cells transduced with AAV-S-TRAIL showed a dose-dependent increase in S-TRAIL secretion with 1,000 MOI leading to 155 F 17 ng/mL S-TRAIL (Fig. 1D) . These results confirm the functionality of fused fluorescent and bioluminescent markers in the bimodal AAV vectors and the secretion of S-TRAIL following transduction by AAV-S-TRAIL.
Next, we investigated the effects of AAV-S-TRAIL on cell viability and caspase activation using three human glioma cell lines known to exhibit varying degrees of TRAIL sensitivity (8) . AAV-S-TRAIL transduction induced a significant decrease in cell viability in Gli36-EGFRvIII (40), with 2,000 MOI leading to a 62% reduction in viability compared with control AAV-Gluc-DsRed2 transduced cells ( Fig. 2A) . Importantly, a corresponding dose-dependent up-regulation in caspase activity was observed in AAV-S-TRAIL transduced Gli36-EGFRvIII cells with 2,000 MOI inducing over a 3-fold increase (Fig. 2B) , whereas no change in caspase activation was observed in control transduced cells. U87 cells exhibited an intermediate level of sensitivity to AAV-S-TRAIL, with 2,000 MOI inducing a 34% reduction in viability that leads to a 1.8-fold increase in caspase activation (Fig. 2C and D) . U251 cells showed the highest level of TRAIL resistance with only high MOI resulting in reduction in cell viability (24% decrease; 10,000 MOI) and caspase activation (1.3-fold increase; 10,000 MOI; Fig. 2E and F) . Taken together, these results suggest that S-TRAIL produced by AAV induces apoptosis in glioma cells, which correlates directly with the activation of caspases. Next, we used a glioma xenograft model to examine the effects of S-TRAIL in vivo. To permit noninvasive longitudinal monitoring of changes in tumor volume, we transduced Gli36-EGFRvIII human glioma cells with LV encoding GFP-Fluc fusion (Gli36-EGFRvIII-GFP-Fluc). Flow cytometry analysis showed that greater than 95% of the cells robustly expressed the GFP fusion (Fig. 3A) . Representative images shown in Fig. 3B revealed that direct delivery of AAV into established Gli36-EGFRvIII-GFP-Fluc could be followed by noninvasive Gluc bioluminescent imaging. Further utilization of serial bioluminescent imaging showed that direct injection of AAV-S-TRAIL led to marked reduction in glioma burden as early as 4 days postinjection compared with control injected gliomas (Fig. 3C ). This reduction in glioma volume was sustained through day 12. Histologic analysis of tumors removed 7 days posttransduction corroborated the in vivo findings showing significant increase in cleaved caspase-3 activation in gliomas treated with S-TRAIL compared with controls (Fig. 3D) . These results show that AAV-S-TRAIL delivered directly into tumors has antitumor effects. Furthermore, bioluminescent imaging permits monitoring of both the delivery of therapeutic AAV and their efficacy in glioma models.
The results of the current study (Fig. 2) , coupled with previous results from our laboratory showing human glioma lines exhibit varied degrees of sensitivity to S-TRAIL (8), emphasize the need for combination therapies to maximize the effectiveness of S-TRAIL therapy. The clinically used chemotherapeutic agent, temozolomide, has been suggested to enhance the toxicity of purified TRAIL (34) . To first investigate the effects of temozolomide alone on glioma lines, cells exhibiting high (Gli36-EGFRvIII) and low (U251) sensitivity to S-TRAIL were incubated with medium containing temozolomide for 24 or 72 h or left untreated. As shown in Fig. 4A to I, temozolomide treatment of both Gli36-EGFRvIII and U251 leads to a significant inhibition in cell cycle indicated by a G 2 -M arrest that was evident at 24 h and persisted through 72 h. This G 2 -M accumulation was associated with a slight increase in the sub-G 1 population (Fig. 4A-I) . Confirming activation of cell cycle checkpoints, Western blot analysis revealed marked increase in the levels of phosphorylated Chk1 following temozolomide treatment and no changes in total Chk1 (Fig. 4J) . A marked increase in the expression of the TRAIL receptor, DR4, starting at 24 h post-treatment was observed following treatment of U251 cells with temozolomide (Fig. 4K) . Alternatively, temozolomide did not increase DR4 expression above the already high levels observed in the highly TRAIL-sensitive Gli36-EGFRvIII cell line (data not shown). These results show that temozolomide inhibits cell cycle progression in glioma cells and increases the expression of death receptors, which may enhance S-TRAIL toxicity in these glioma lines. , and U251 (E and F) human glioma cells were transduced with S-TRAIL or Gluc-DsRed2 at increasing MOI (1,000-10,000), and 24 h post-transduction, both cell viability (A, C, and E) and caspase activation (B, D, and F) were determined using bioluminescent-based assays. *, P < 0.05 versus control.
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Mol Cancer Ther 2008;7 (11 To determine if temozolomide enhances S-TRAILinduced cell killing, two approaches were used: (a) concomitant S-TRAIL and temozolomide treatment and (b) presensitization with temozolomide before S-TRAIL treatment. To this end, two glioma cell lines with varying degrees of TRAIL sensitivity were cotreated with AAV-S-TRAIL (0-4,000 MOI) or NSC-S-TRAIL (0-600 ng/mL) and increasing concentrations of temozolomide (0-1,000 Amol/L). Summary data shown in Fig. 5A show that cell viability in the highly TRAIL-sensitive Gli36-EGFRvIII cell line was markedly reduced by combined AAV-S-TRAIL/temozolomide treatment compared with either therapy alone. A similar reduction was observed in Gli36-EGFRvIII treated with NSC-S-TRAIL/temozolomide (Fig. 5B) . In U251 cells that exhibited the highest resistance to S-TRAIL monotherapy, a modest yet significant increase in cell killing was observed in groups treated with AAV-S-TRAIL/temozolomide or NSC-S-TRAIL/temozolomide cotherapy ( Fig. 5C  and D) .
To investigate if temozolomide pretreatment can overcome S-TRAIL resistance and to sensitize cells to combined S-TRAIL and temozolomide therapy, we first treated the minimally TRAIL sensitive U251 cells for 24 h with temozolomide alone. Following this initial sensitization, temozolomide was refreshed at which time AAV-S-TRAIL or NSC-S-TRAIL was added at low (1,000 MOI; 200 ng/mL) and high doses (4,000 MOI; 600 ng/mL). In separate groups, nonsensitized cells were treated with temozolomide and S-TRAIL simultaneously. Showing the potential effectiveness of temozolomide sensitization for overcoming S-TRAIL resistance, summary graphs shown in Fig. 6A and B show that sensitization of cells by 24 h of temozolomide pretreatment significantly enhanced cell killing of S-TRAIL/temozolomide treatment compared with cells not sensitized before S-TRAIL/temozolomide addition. In U251 cells treated with NSC-S-TRAIL, enhanced killing by temozolomide sensitization was associated with a marked increase in caspase-3/7 activation (Fig. 6C) as well as an increase in the levels of the apoptotic marker cleaved poly(ADP-ribose) polymerase (Fig. 6D) compared with nonsensitized cells. Additionally, immunocytochemistry confirmed a significant increase in the levels of cleaved caspase-3 in cells sensitized by temozolomide (Fig. 6E) . These results show pretreatment of cells with temozolomide significantly increases the sensitivity of U251 glioma cells to S-TRAIL-induced apoptosis.
Discussion
Recent work in our laboratory led to the generation of a recombinant form of soluble TRAIL consisting of the extracellular domain of TRAIL fused to the extracellular domain of Flt3L by a leucine zipper (S-TRAIL; ref. 5). We have shown that S-TRAIL has significantly enhanced antitumor effects compared with TRAIL alone (5) and that the antiglioma effects of S-TRAIL produced by NSC can be enhanced through synergistic inhibition of antiapoptotic pathways (8) or up-regulated microRNAs (23) . In this study, we have engineered novel bimodal AAV vectors encoding fluorescent (DsRed2) and bioluminescent (Gluc) markers and S-TRAIL and have shown the effectiveness of AAV-S-TRAIL as monotherapy in mouse tumor models. Furthermore, we have shown that temozolomide treatment sensitizes glioma cell lines least sensitive to S-TRAIL. In the endogenous form, TRAIL is expressed as a type II membrane-bound protein that functions as a key component of the immune system interacting with death receptors to aid in immune surveillance (41) . Despite being a membrane-bound protein, the extracellular domain of TRAIL can be cleaved leading to soluble form of TRAIL that still exhibits robust tumor cell killing in vitro and in vivo. Extending this research to the clinics, Genentech and Amgen have recently initiated clinical trials to test the tumor-killing potential of soluble TRAIL in cancer patients. Current clinical trials are focused on the systemic delivery of purified TRAIL, an approach that suffers from several limitations including inefficient delivery of TRAIL to the primary glioma mass and potentially increased toxicity to normal tissue (7) . Recently, other studies have focused on TRAIL delivery (3, 5, 35, 42) . Previous results from our laboratory showed that therapeutic NSC-S-TRAIL represents a novel means to selectively target glioma masses, whereas the capacity to differentiate into cells of neural lineage suggests that therapeutic NSC may be able to replace neural tissue damaged by the glioma (3, 23, 27 ). Due to their tropism for tumor masses and ability to be engineered to secrete antitumor therapies, stem cells could be well suited for treating gliomas. However, in instances where antitumor therapies are toxic to stem cells, unable to be secreted, require a higher dose than can be delivered by stem cells, or the host rejects stem cell engraftment, direct injection of viral vectors into tumors may prove advantageous. As such, several viral vectors have been used clinically; however, one of the most promising among these is AAV. AAV transduction occurs in both dividing and nondividing cells (20) , leads to high levels of transgene expression, and can persist for several months in the brain (43) . Furthermore, AAV has entered clinical trials and has been shown to have several beneficial effects over other viral vectors (reviewed in refs. 20, 28) . Based on this, we developed a novel AAV-S-TRAIL as an alternative to NSC-S-TRAIL. The results of this study show that transduction of glioma cells with AAV-S-TRAIL leads to glioma cell killing in vitro and in vivo as assessed by serial bioluminescent imaging. These results suggest that the high transduction efficiency and prolonged transgene expression achieved by direct delivery of AAV-S-TRAIL offer the potential to deliver high levels of S-TRAIL therapy to localized regions of the glioma, thus minimizing toxicity to surrounding or systemic tissue. Further, the inclusion of Gluc-DsRed2 fusion proteins in this vector permits simple and noninvasive monitoring of viral gene expression that should allow easy determination of transduction efficiency and duration of expression in vivo, both vital criteria for achieving effective viral gene therapy. To our knowledge, this study is the first to show utility of AAV encoding TRAIL to treat malignant human glioma cells lines.
A large percentage of primary glioma lines are resistant to TRAIL-induced apoptosis (15, 16) and numerous studies have shown the potential of sensitizing TRAIL-resistant tumor cell lines by combining TRAIL with chemotherapeutic agents (8, 23, 34, 44) . In this study, we show that TRAIL sensitivity can be enhanced both in lines already sensitive to TRAIL and, more importantly, in TRAILresistant cell lines. At concentrations as low as 100 Amol/L, temozolomide significantly increased the killing effects of S-TRAIL in Gli36-EGFRvIII. In U251 cell lines, the sensitization of cells required 24 h of pretreatment with temozolomide alone to induce TRAIL sensitivity; however, following this treatment, combined temozolomide and S-TRAIL leads to greater than 60% reduction in cell viability in this line, which showed minimal sensitivity to S-TRAIL therapy alone. The oral chemotherapy temozolomide (31), S-TRAIL (7), AAV vectors (28), and cell-based (45) therapies are all being used in the clinics. Temozolomide has been implemented as part of the standard of care for patients being treated for glioblastoma. Clinical trials with TRAIL have relied primarily on the injection of purified protein, a method that has proven inefficient. The results of this study suggest that the combination of these clinically relevant therapies may improve their delivery and potency, thus leading to improved outcomes for patients.
TRAIL-induced apoptosis is a receptor-mediated pathway, triggered on binding of TRAIL to death receptors (6, 7) . Treatment of glioma cells with NSC-S-TRAIL leads to the introduction of fully functional TRAIL that can immediately activate death receptors to initiate apoptosis. In contrast, transduction of glioma cells with AAV-S-TRAIL requires cellular uptake of the virus, uncoating, integration into the cell nucleus, expression, and processing of S-TRAIL, which is then secreted (20) . It is only after this secretion that we expect functional S-TRAIL to be present in the medium and capable of binding to the death receptor pathways to induce apoptosis. Therefore, we anticipate that the increased effectiveness of NSC-S-TRAIL is most likely due to this rapid death receptor binding and apoptotic induction compared with the delayed activation triggered by AAV-S-TRAIL transduction. However, both S-TRAIL delivered by either NSC or AAV proved to have potent antiglioma effects that were synergistically enhanced by temozolomide cotherapy.
In this study, we observed temozolomide-induced accumulation of cells in G 2 -M phase that was associated with up-regulation of death receptors. Several studies have clearly shown the capacity of temozolomide to induce cell cycle arrest in glioma lines. This effect is typically mediated by activation of the ATM/ATR pathways in response to DNA damage, which subsequently activates downstream cell cycle checkpoints to inhibit cell cycle progression (46 -48) . Various therapeutic agents have been shown to increase the expression of death receptors, including radiation (48), topoisomerase inhibitors (49) , and methylating agents (49) . As TRAIL toxicity is mediated by receptor binding, receptor up-regulation provides a clear link for the mechanism underlying the synergy observed between TRAIL and these antiglioma therapies. In this study, we observed temozolomide-induced up-regulation of DR4 as early as 24 h post-temozolomide treatment that remained elevated through 72 h. The increase in DR4 expression was paralleled by increased accumulation of cells in G 2 -M phase and activation of Chk1. These results suggest that temozolomide and TRAIL synergism involves two mechanisms: (a) increase of death receptor expression in lines with low basal expression permitting increased TRAIL receptor binding and (b) inhibition of cell proliferation in parallel with TRAIL-induced apoptosis. As such, the first mechanism will predominate in slow proliferating cell lines with low DR4 expression (U251), whereas the second mechanism will predominate in faster proliferating cell lines with high DR4 expression (Gli36-EGFRvIII). Additional investigation will be required to elucidate the exact mechanism of temozolomide and TRAIL synergy in various cell lines; however, it is becoming increasingly clear that one of the key events underlying TRAIL/temozolomide synergy is increased expression of death receptors.
In conclusion, we have shown that antitumor effects of S-TRAIL delivered by novel means are enhanced by cotreatment with the clinical chemotherapeutic agent temozolomide. We anticipate that further investigation in vivo using S-TRAIL delivered by AAV or NSC and temozolomide will pave a way for their combined use in clinics. One could envision the integration of TRAIL 
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